Investor Highlights

Commsec Executive Series

Pharmaxis Ltd (PXS) MD, Gary Phillips speaks with Tom Piotrowski about the company’s broad pipeline of drug candidates, large licence deal with Boehringer & upcoming Phase 2 clinical results for NASH.

Watch interview

CEO Presentation to 2019 AGM

Presentation by the Pharmaxis CEO and CFO to the 2019 AGM

View presentation – pdf

Shareholder Update - September 2019

Shareholder update for the quarter ended 30 September 2019

Read quarterly update - pdf

Pharmaxis Science Update Outlines Scope for Anti-Fibrotic Pipeline

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today provided an update on the company’s anti-fibrotic drug pipeline highlighting both the therapeutic areas of interest and competitive positioning of its LOXL2 and pan LOX inhibitors.

Speaking at the 2019 AusBiotech conference in Melbourne, Australia, Pharmaxis CEO Gary Phillips outlined the steps Pharmaxis has taken to develop a best in class status for its Lysyl oxidase like 2 (LOXL2) inhibitors and strong pre-clinical data in myelofibrosis for its pan-LOX inhibitor PXS-5505.

Read full media release - pdf